See more : New Century Group Hong Kong Limited (0234.HK) Income Statement Analysis – Financial Results
Complete financial analysis of Sol-Gel Technologies Ltd. (SLGL) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Sol-Gel Technologies Ltd., a leading company in the Biotechnology industry within the Healthcare sector.
- Carnival Corporation & plc (CCL) Income Statement Analysis – Financial Results
- Solar Company S.A. (SOL.WA) Income Statement Analysis – Financial Results
- Biomotion Sciences Ordinary Shares (SLXN) Income Statement Analysis – Financial Results
- Taiwan Cogeneration Corporation (8926.TW) Income Statement Analysis – Financial Results
- Societe de Tayninh SA (TAYN.PA) Income Statement Analysis – Financial Results
Sol-Gel Technologies Ltd. (SLGL)
About Sol-Gel Technologies Ltd.
Sol-Gel Technologies Ltd., a clinical stage specialty pharmaceutical company, focuses on developing and commercializing topical dermatological drug products based on its proprietary microencapsulation delivery system in Israel. The company's lead product candidates include Twyneo, a novel, once-daily, non-antibiotic topical cream which has completed Phase III clinical trials for the treatment of acne vulgaris; Epsolay, a once-daily topical cream that has completed Phase III clinical trials for the treatment of papulopustular rosacea; SGT-210, which is in Phase I clinical trial for the treatment of palmoplantar keratoderma; and Erlotinib, Tapinarof, and roflumilast to treat psoriasis and other medical conditions. It is also involved in the development of generic topical dermatological drug products. The company has collaboration with Perrigo. Sol-Gel Technologies Ltd. was incorporated in 1997 and is headquartered in Ness Ziona, Israel.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 1.55M | 3.88M | 31.27M | 8.77M | 22.90M | 129.00K | 174.00K | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 23.54M | 12.68M | 20.38M | 27.91M | 40.58M | 28.15M | 300.00K | 359.00K | 300.00K | 0.00 |
| Gross Profit | -21.99M | -8.80M | 10.89M | -19.14M | -17.67M | -28.02M | -126.00K | -359.00K | -300.00K | 0.00 |
| Gross Profit Ratio | -1,414.86% | -226.60% | 34.83% | -218.24% | -77.17% | -21,718.60% | -72.41% | 0.00% | 0.00% | 0.00% |
| Research & Development | 23.54M | 12.68M | 20.38M | 27.91M | 40.58M | 28.15M | 25.81M | 17.02M | 7.18M | 2.93M |
| General & Administrative | 7.37M | 7.45M | 8.45M | 11.09M | 8.28M | 5.50M | 6.00M | 3.73M | 2.46M | 1.88M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 7.37M | 7.45M | 8.45M | 11.09M | 8.28M | 5.50M | 6.00M | 3.73M | 2.46M | 1.88M |
| Other Expenses | -55.00K | 0.00 | -524.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 30.86M | 20.13M | 28.31M | 39.00M | 48.85M | 33.65M | 31.81M | 20.76M | 9.65M | 4.81M |
| Cost & Expenses | 30.86M | 20.13M | 28.31M | 39.00M | 48.85M | 33.65M | 31.81M | 20.76M | 9.65M | 4.81M |
| Interest Income | 2.07M | 1.32M | 257.00K | 943.00K | 1.37M | 0.00 | 0.00 | 0.00 | 0.00 | 40.00K |
| Interest Expense | 0.00 | 1.32M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 342.00K | 562.00K | 880.00K | 946.00K | 887.00K | 762.00K | 300.00K | 359.00K | 300.00K | 225.00K |
| EBITDA | -28.96M | -15.68M | 3.84M | -29.29M | -25.06M | -32.76M | -31.16M | -20.40M | -9.35M | -4.58M |
| EBITDA Ratio | -1,863.77% | -403.86% | 9.48% | -344.69% | -109.43% | -25,394.57% | -17,909.20% | 0.00% | 0.00% | 0.00% |
| Operating Income | -29.31M | -16.24M | 2.08M | -30.23M | 25.95M | -33.52M | -31.63M | -20.76M | -9.65M | -4.81M |
| Operating Income Ratio | -1,885.78% | -418.34% | 6.66% | -344.69% | 113.30% | -25,985.27% | -18,179.89% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 2.07M | 1.32M | 257.00K | 943.00K | 1.37M | 1.32M | 65.00K | -15.00K | -13.00K | -40.00K |
| Income Before Tax | -27.24M | -14.92M | 3.22M | -29.29M | -24.58M | -32.20M | -31.57M | -20.77M | -9.66M | -4.85M |
| Income Before Tax Ratio | -1,752.77% | -384.32% | 10.30% | -333.94% | -107.30% | -24,963.57% | -18,142.53% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | -1.32M | -1.14M | -1.89M | 33.00K | -1.32M | -65.00K | 15.00K | 13.00K | 0.00 |
| Net Income | -27.24M | -13.60M | 4.36M | -27.40M | -24.61M | -32.20M | -31.57M | -20.77M | -9.66M | -4.85M |
| Net Income Ratio | -1,752.77% | -350.30% | 13.94% | -312.40% | -107.44% | -24,963.57% | -18,142.53% | 0.00% | 0.00% | 0.00% |
| EPS | -1.01 | -0.59 | 0.19 | -1.21 | -1.26 | -1.80 | -1.76 | -1.77 | -0.82 | -1.81 |
| EPS Diluted | -1.01 | -0.59 | 0.18 | -1.21 | -1.26 | -1.80 | -1.76 | -1.77 | -0.82 | -1.81 |
| Weighted Avg Shares Out | 27.09M | 23.13M | 23.06M | 22.57M | 19.53M | 17.87M | 17.99M | 11.74M | 11.74M | 2.68M |
| Weighted Avg Shares Out (Dil) | 27.09M | 23.13M | 23.57M | 22.57M | 19.53M | 17.87M | 17.99M | 11.74M | 11.74M | 2.68M |
Sol-Gel Technologies and Galderma Announce Exclusive Licenses for the Commercialization of EPSOLAY® and TWYNEO® in the United States
Sol-Gel Technologies Reports First Quarter 2021 Financial Results and Corporate Update
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors Sol-Gel Technologies Ltd. - SLGL
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors Sol-Gel Technologies Ltd. - SLGL
Sol-Gel Technologies Provides Update on FDA Review of EPSOLAY®
SolGel Technologies Ltd. (SLGL) Moves 9.7% Higher: Will This Strength Last?
SolGel Technologies Ltd. (SLGL) Stock Jumps 10.8%: Will It Continue to Soar?
SolGel Technologies Ltd. (SLGL) Reports Q4 Loss, Lags Revenue Estimates
Sol-Gel Technologies Reports Full Year 2020 Financial Results and Corporate Update
Sol-Gel Technologies to Present at Upcoming 2021 Raymond James Institutional Investors Conference and H.C. Wainwright Global Life Sciences Conference
Source: https://incomestatements.info
Category: Stock Reports